0001209191-22-020984.txt : 20220324 0001209191-22-020984.hdr.sgml : 20220324 20220324192404 ACCESSION NUMBER: 0001209191-22-020984 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220322 FILED AS OF DATE: 20220324 DATE AS OF CHANGE: 20220324 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schroeder Thilo CENTRAL INDEX KEY: 0001776412 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39219 FILM NUMBER: 22767885 MAIL ADDRESS: STREET 1: C/O NEXTECH INVEST LTD. STREET 2: BAHNHOFSTRASSE 18 CITY: ZURICH STATE: V8 ZIP: 8001 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Revolution Medicines, Inc. CENTRAL INDEX KEY: 0001628171 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 472029180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 700 SAGINAW DR CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 415-766-3638 MAIL ADDRESS: STREET 1: 700 SAGINAW DR CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-03-22 0 0001628171 Revolution Medicines, Inc. RVMD 0001776412 Schroeder Thilo C/O REVOLUTION MEDICINES, INC. 700 SAGINAW DRIVE REDWOOD CITY CA 94063 1 0 0 0 Common Stock 2022-03-22 4 P 0 5440 22.15 A 701666 I By Nextech Crossover I SCSP Common Stock 2022-03-22 4 P 0 71186 23.18 A 772852 I By Nextech Crossover I SCSP Common Stock 2022-03-22 4 P 0 53501 23.69 A 826353 I By Nextech Crossover I SCSP Common Stock 2022-03-23 4 P 0 37708 23.61 A 864061 I By Nextech Crossover I SCSP Common Stock 2022-03-23 4 P 0 15410 23.99 A 879471 I By Nextech Crossover I SCSP Common Stock 2022-03-24 4 P 0 49119 24.26 A 928590 I By Nextech Crossover I SCSP Common Stock 2668214 I By Nextech V Oncology S.C.S., SICAV-SIF Common Stock 300000 I By Nextech VI Oncology SCSp The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.49 to $22.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.50 to $23.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.50 to $23.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.88 to $23.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.88 to $24.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.85 to $24.68 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. /s/ Darren DeStefano, Attorney-in-Fact 2022-03-24